Study of Pharmacokinetic, Safety, Immunogenicity and Efficacy of CMAB819 and Nivolumab in R/M HNSCC
Phase 1
Terminated
- Conditions
- Squamous Cell Carcinoma of the Head and Neck
- Interventions
- First Posted Date
- 2020-12-09
- Last Posted Date
- 2024-04-09
- Lead Sponsor
- Taizhou Mabtech Pharmaceutical Co.,Ltd
- Target Recruit Count
- 21
- Registration Number
- NCT04659369
- Locations
- 🇨🇳
Shanghai East Hospital, Shanghai, Shanghai, China
Pharmacokinetic, Safety and Immunogenicity Study of CMAB809 and Herceptin in Healthy Volunteers
- First Posted Date
- 2019-08-08
- Last Posted Date
- 2020-10-14
- Lead Sponsor
- Taizhou Mabtech Pharmaceutical Co.,Ltd
- Target Recruit Count
- 72
- Registration Number
- NCT04049409
- Locations
- 🇨🇳
Shanghai Xuhui Central Hospital, Shanghai, Shanghai, China
CMAB009 Combined With FOLFIRI First-line Treatment in Patients With RAS/BRAF Wild-type, Metastatic Colorectal Cancer
Phase 3
Completed
- Conditions
- Metastatic Colorectal Cancer
- Interventions
- First Posted Date
- 2017-07-02
- Last Posted Date
- 2024-11-07
- Lead Sponsor
- Taizhou Mabtech Pharmaceutical Co.,Ltd
- Target Recruit Count
- 520
- Registration Number
- NCT03206151
- Locations
- 🇨🇳
Cancer hospital Chinese academy of medical sciences, Beijing, Beijing, China
🇨🇳Tianjing medical university cancer institute and hospital, Tianjin, Tianjin, China
© Copyright 2025. All Rights Reserved by MedPath